Phase I/II study of docetaxel (Taxotere) in combination with doxorubicin HCI liposome injection (Doxil) in advanced androgen-independent prostate cancer (AIPC)
Phase of Trial: Phase I/II
Latest Information Update: 07 Jan 2013
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Jul 2010 Planned end date (1 Nov 2010) added as reported by ClinicalTrials.gov.
- 06 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.